174 related articles for article (PubMed ID: 19184022)
21. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
22. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.
Horita K; Yamaguchi A; Hirose K; Ishida M; Noriki S; Imamura Y; Fukuda M
Eur J Histochem; 2001; 45(1):73-84. PubMed ID: 11411868
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
25. Pathobiology of HER 2 positive small invasive (T1a,b) breast cancer: "A wolf in sheep's clothing".
Bezić J; Šamija Projić I; Projić P; Meljanac Salopek K; Živković PM; Božić J; Tomić S
Pathol Res Pract; 2017 Dec; 213(12):1510-1514. PubMed ID: 29033181
[TBL] [Abstract][Full Text] [Related]
26. Breast conservative surgery and local recurrence.
Rezai M; Kraemer S; Kimmig R; Kern P
Breast; 2015 Nov; 24 Suppl 2():S100-7. PubMed ID: 26432359
[TBL] [Abstract][Full Text] [Related]
27. Prognostic and predictive factors in early-stage breast cancer.
Cianfrocca M; Goldstein LJ
Oncologist; 2004; 9(6):606-16. PubMed ID: 15561805
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis.
Davis BW; Gelber R; Goldhirsch A; Hartmann WH; Hollaway L; Russell I; Rudenstam CM
Hum Pathol; 1985 Dec; 16(12):1212-8. PubMed ID: 3905576
[TBL] [Abstract][Full Text] [Related]
29. HER2 as a prognostic factor in breast cancer.
Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
[TBL] [Abstract][Full Text] [Related]
30. A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma.
Sun JM; Han W; Im SA; Kim TY; Park IA; Noh DY; Heo DS; Bang YJ; Choe KJ; Kim NK
Cancer; 2004 Dec; 101(11):2516-22. PubMed ID: 15517588
[TBL] [Abstract][Full Text] [Related]
31. Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients.
Gago FE; Tello OM; Diblasi AM; Ciocca DR
J Steroid Biochem Mol Biol; 1998 Dec; 67(5-6):431-7. PubMed ID: 10030692
[TBL] [Abstract][Full Text] [Related]
32. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
Tas F
Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
[TBL] [Abstract][Full Text] [Related]
33. Predictive parameters for internal mammary node drainage in patients with early breast cancer.
Lukesova L; Vrana D; Gatek J; Koranda P; Cwiertka K; Radova L; Melichar B; Prouzova Z; Sramek V; Svach I
Tumori; 2014; 100(3):254-8. PubMed ID: 25076234
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of steroid hormone receptors and histopathological characterization of human breast cancer.
Reiner A; Kolb R; Reiner G; Jakesz R; Schemper M; Spona J
J Cancer Res Clin Oncol; 1987; 113(3):285-90. PubMed ID: 3584218
[TBL] [Abstract][Full Text] [Related]
35. Association between molecular subtypes and lymph node status in invasive breast cancer.
Si C; Jin Y; Wang H; Zou Q
Int J Clin Exp Pathol; 2014; 7(10):6800-6. PubMed ID: 25400761
[TBL] [Abstract][Full Text] [Related]
36. Characterization and clinical impact of residual disease after neoadjuvant chemotherapy.
Viale G
Breast; 2013 Aug; 22 Suppl 2():S88-91. PubMed ID: 24074800
[TBL] [Abstract][Full Text] [Related]
37. Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer.
Masarwah A; Auvinen P; Sudah M; Dabravolskaite V; Arponen O; Sutela A; Oikari S; Kosma VM; Vanninen R
BMC Cancer; 2016 Nov; 16(1):833. PubMed ID: 27806715
[TBL] [Abstract][Full Text] [Related]
38. Can we identify the group of small invasive (T1a,b) breast cancers with minimal risk of axillary lymph node involvement? A pathohistological and DNA flow cytometric study.
Bezić J; Samija-Projić I; Projić P; Ljubković J; Capkun V; Tomić S
Pathol Res Pract; 2011 Jul; 207(7):438-42. PubMed ID: 21689895
[TBL] [Abstract][Full Text] [Related]
39. The analysis of prognostic factors in stage III-B non-inflammatory breast cancer.
Yildirim E; Semerci E; Berberoğlu U
Eur J Surg Oncol; 2000 Feb; 26(1):34-8. PubMed ID: 10718177
[TBL] [Abstract][Full Text] [Related]
40. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators.
Lah TT; Cercek M; Blejec A; Kos J; Gorodetsky E; Somers R; Daskal I
Clin Cancer Res; 2000 Feb; 6(2):578-84. PubMed ID: 10690542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
